Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Dorzolamide Hydrochloride

FDA-approved product (solution/drops, ophthalmic), marketed as Dorzolamide Hydrochloride, Trusopt.

Registered studies
50+
Lab records
4
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Dorzolamide Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Glaucoma
  • Ocular hypertension
  • Open-angle glaucoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Carbonic anhydrase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA44.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli39.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis86.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • M. tuberculosis: measured active in 4 of 4 lab records
Open Dorzolamide Hydrochloride in ChEMBL Registered studies below
Show the 4 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Dorzolamide Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Safety and Efficacy of Brinzolamide Dosed TID With Dorzolamide Dosed TID in Reducing Intraocular Pressure in Patients With Open Angle Glaucoma or Ocular Hypertension

    NCT00761995 · start 2009-02

    Registered record
    Registry ID
    NCT00761995
    Conditions
    Glaucoma; Ocular Hypertension
    Interventions
    Azopt; Cosopt
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-02
    Completion
    2010-07
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma; Ocular Hypertension
    InterventionAzopt; Cosopt
    PhasePhase 4
    Registry statusCompleted

  • 24-hr Intraocular Pressure Control With Dorzolamide/Timolol vs the Brimonidine/Timolol Fixed Combination

    NCT00972257 · start 2009-01

    Registered record
    Registry ID
    NCT00972257
    Conditions
    Glaucoma
    Interventions
    treatment with dorzolamide/timolol; treatment with brimonidine/timolol
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-01
    Completion
    2009-09
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma
    Interventiontreatment with dorzolamide/timolol; treatment with brimonidine/timolol
    PhasePhase 4
    Registry statusCompleted

  • Effects of Cosopt on IOP and on Ocular Diastolic Perfusion Pressure

    NCT00796198 · start 2008-12

    Registered record
    Registry ID
    NCT00796198
    Conditions
    Glaucoma
    Interventions
    Xalatan+Cosopt; Xalatan
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2008-12
    Completion
    2009-07
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma
    InterventionXalatan+Cosopt; Xalatan
    PhasePhase 4
    Registry statusUnknown

  • Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Blood Flow

    NCT00811850 · start 2008-12

    Registered record
    Registry ID
    NCT00811850
    Conditions
    Glaucoma
    Interventions
    fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution; fixed combination of dorzolamide hydrochloride timolol maleate ophthalmic solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-12
    Completion
    2009-12
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma
    Interventionfixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution; fixed combination of dorzolamide hydrochloride timolol maleate ophthalmic solution
    PhasePhase 4
    Registry statusCompleted

  • The Effects of Cosopt® Vs Xalacom® on Ocular Hemodynamics and Intraocular Pressure (IOP) in Primary Open-angle Glaucoma (POAG)

    NCT00815373 · start 2008-12

    Registered record
    Registry ID
    NCT00815373
    Conditions
    Open-Angle Glaucoma; Ocular Hypertension
    Interventions
    Dorzolamide+Timolol Maleate0.5%; Latanoprost+Timolol Maleate0.5%+Lytears
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2008-12
    Completion
    2012-06
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen-Angle Glaucoma; Ocular Hypertension
    InterventionDorzolamide+Timolol Maleate0.5%; Latanoprost+Timolol Maleate0.5%+Lytears
    PhaseNot applicable
    Registry statusWithdrawn

  • Effects of Common Topical Glaucoma Therapy on Optic Nerve Head Blood Flow Autoregulation During Increased Arterial Blood Pressure and Artificially Elevated Intraocular Pressure in Healthy Humans

    NCT00275756 · start 2008-09

    Registered record
    Registry ID
    NCT00275756
    Conditions
    Glaucoma
    Interventions
    Timolol (drug); dorzolamide (drug); brimonidine (drug); Laser Doppler flowmetry; Goldmann applanation tonometer; Suction cup method
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2008-09
    Completion
    2014-11
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma
    InterventionTimolol (drug); dorzolamide (drug); brimonidine (drug); Laser Doppler flowmetry +2 more
    PhaseNot applicable
    Registry statusWithdrawn

  • Patient Preference Study

    NCT00576342 · start 2007-12

    Registered record
    Registry ID
    NCT00576342
    Conditions
    Glaucoma; Ocular Hypertension
    Interventions
    AL-3862+timolol ophthalmic suspension; Dorzolamide+timolol ophthalmic solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-12
    Completion
    2008-01
    Enrolment
    129

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma; Ocular Hypertension
    InterventionAL-3862+timolol ophthalmic suspension; Dorzolamide+timolol ophthalmic solution
    PhasePhase 3
    Registry statusCompleted

  • Pharmacological Intervention in Diabetic Retinopathy

    NCT00619034 · start 2007-09

    Registered record
    Registry ID
    NCT00619034
    Conditions
    Diabetic Retinopathy
    Interventions
    Latanoprost, diclofenac and dorzolamide (eyedrops); Diclofenac; Dorzolamide
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2007-09
    Completion
    2010-12
    Enrolment
    87

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetic Retinopathy
    InterventionLatanoprost, diclofenac and dorzolamide (eyedrops); Diclofenac; Dorzolamide
    PhaseNot applicable
    Registry statusCompleted

  • Additive Intra-ocular Pressure Reduction Effect of Fixed Combination of Maleate Timolol 0.5%/Dorzolamide 2% on Monotherapy With Latanoprost in Patients With Elevated Intra-ocular Pressure

    NCT00906594 · start 2007-09

    Registered record
    Registry ID
    NCT00906594
    Conditions
    Glaucoma
    Interventions
    latanoprost
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-09
    Completion
    2008-07
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma
    Interventionlatanoprost
    PhasePhase 4
    Registry statusCompleted

  • Dry Eye Study With Cosopt® Over 8 Weeks in Patients With Open-Angle Glaucoma or Ocular Hypertension (0507A-152)(COMPLETED)

    NCT00545064 · start 2007-05-23

    Registered record
    Registry ID
    NCT00545064
    Conditions
    Ocular Hypertension; Open Angle Glaucoma
    Interventions
    dorzolamide hydrochloride (+) timolol maleate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-05-23
    Completion
    2008-09-15
    Enrolment
    176

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOcular Hypertension; Open Angle Glaucoma
    Interventiondorzolamide hydrochloride (+) timolol maleate
    PhasePhase 4
    Registry statusCompleted

  • Comparison of Efficacy of Two Groups of Glaucoma Drops (Xalatan vs.Cosopt) in Reducing Eye Pressure Following Laser (SLT)Treatment in the Management of Glaucoma.

    NCT00440336 · start 2006-10

    Registered record
    Registry ID
    NCT00440336
    Conditions
    Open Angle Glaucoma
    Interventions
    Cosopt; Xalatan
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2006-10
    Completion
    Not recorded
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen Angle Glaucoma
    InterventionCosopt; Xalatan
    PhaseNot applicable
    Registry statusUnknown

  • 24-hour Study of Dorzolamide/Timolol and Latanoprost/Timolol Fixed Combinations

    NCT00397241 · start 2006-09

    Registered record
    Registry ID
    NCT00397241
    Conditions
    Open-angle Glaucoma
    Interventions
    Drug: dorzolamide/timolol; Drug: latanoprost/timolol; dorzolamide/timolol and latanoprost; placebo (artificial tears)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-09
    Completion
    2007-12
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen-angle Glaucoma
    InterventionDrug: dorzolamide/timolol; Drug: latanoprost/timolol; dorzolamide/timolol and latanoprost; placebo (artificial tears)
    PhasePhase 4
    Registry statusCompleted

  • Circadian Rhythms of Aqueous Humor Dynamics in Humans

    NCT00572936 · start 2006-03-13

    Registered record
    Registry ID
    NCT00572936
    Conditions
    Glaucoma
    Interventions
    Latanoprost; Dorzolamide; Timolol
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-03-13
    Completion
    2009-11-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma
    InterventionLatanoprost; Dorzolamide; Timolol
    PhasePhase 2
    Registry statusCompleted

  • Assessing Cosopt Switch Patients

    NCT00273442 · start 2005-11

    Registered record
    Registry ID
    NCT00273442
    Conditions
    Ocular Hypertension; Open-Angle Glaucoma; Exfoliation Syndrome; Glaucoma, Pigmentary
    Interventions
    timolol maleate; dorzolamide/timolol maleate fixed combination
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-11
    Completion
    2007-04
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOcular Hypertension; Open-Angle Glaucoma; Exfoliation Syndrome; Glaucoma, Pigmentary
    Interventiontimolol maleate; dorzolamide/timolol maleate fixed combination
    PhasePhase 4
    Registry statusCompleted

  • Treatment of Cystoid Macular Edema in Patients With Retinal Degeneration

    NCT00716586 · start 2005-10

    Registered record
    Registry ID
    NCT00716586
    Conditions
    Retinal Degenerations
    Interventions
    2% dorzolamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-10
    Completion
    2017-11-17
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRetinal Degenerations
    Intervention2% dorzolamide
    PhasePhase 4
    Registry statusCompleted